A Sector Under Pressure to Move Faster With Less
The U.S. veterinary pharmaceuticals market reached approximately $12.4 billion in 2024, according to data from the American Veterinary Medical Association Economic Summary, and the pace of new product approvals from the FDA Center for Veterinary Medicine has accelerated meaningfully over the past three years. Yet most veterinary pharmaceutical companies—particularly those outside the top five global manufacturers—operate with commercial teams that are significantly smaller than their human pharmaceutical counterparts.
The mismatch between growth ambition and staffing capacity has made virtual assistants one of the most pragmatic operational investments available to veterinary pharma companies today. A dedicated VA can absorb administrative workflows that would otherwise require one or more full-time coordinators, giving lean teams the bandwidth to focus on scientific and commercial priorities.
Regulatory Affairs Support
Veterinary drug approvals in the United States require New Animal Drug Applications (NADAs) or Abbreviated NADAs (ANADAs) submitted to FDA-CVM. The documentation burden for these filings is substantial, and maintaining audit-ready records throughout the product lifecycle adds ongoing administrative weight.
Virtual assistants trained in regulatory document management can organize submission packages, track correspondence deadlines, manage CMC documentation filing systems, and coordinate label review workflows. According to a 2024 survey by the Regulatory Affairs Professionals Society (RAPS), regulatory coordinators in veterinary pharma spend an average of 14 hours per week on document management tasks that do not require specialized scientific judgment—precisely the work VAs can take over.
Veterinary Sales Team Coordination
Veterinary pharmaceutical sales teams typically cover large geographic territories and rely heavily on clinic visit scheduling, sample fulfillment tracking, and follow-up communication. Virtual assistants provide back-office support to field reps by managing CRM data entry, scheduling confirmations, territory route planning support, and inbound clinic inquiry handling.
"We doubled the call capacity of our four-rep field team by pairing each rep with a shared VA," said a VP of sales at a small-animal pharmaceutical company during a 2025 Animal Health Industry conference panel. "The VA handles everything that doesn't require a rep to be physically present."
Medical Information and Adverse Event Intake
FDA-CVM requirements mandate that veterinary pharmaceutical companies maintain pharmacovigilance programs, including adverse event intake and reporting. VAs can staff first-line intake queues, apply standardized triage protocols, and route reportable events to medical affairs reviewers—reducing response time while maintaining compliance.
A 2024 benchmarking report from the Veterinary Pharmacovigilance Consortium found that companies using trained remote coordinators for adverse event intake reduced average triage time by 38% compared to companies relying solely on field staff to self-report.
Market Access and Pricing Research
Formulary placement, state-level compounding pharmacy regulations, and pricing dynamics in the veterinary channel vary significantly by geography and product category. VAs provide ongoing competitive intelligence by monitoring trade publications, aggregating pricing data from distributor portals, and flagging regulatory changes with potential commercial impact.
Cost Structure Comparison
A regulatory affairs coordinator in the veterinary pharmaceutical sector commands a median annual salary of $68,000–$82,000 in the United States, according to 2024 Bureau of Labor Statistics occupational data, with total employment cost typically 28–32% above base. High-quality VA services typically cost $2,000–$4,500 per month depending on specialization and hours, representing a meaningful savings for companies managing multiple product lines.
Companies looking for proven remote staffing with the capacity to support life sciences workflows can explore options at Stealth Agents, which places VAs with documented experience in regulated industries.
The Road Ahead
As FDA-CVM continues modernizing its approval processes and veterinary pharmaceutical companies look to diversify species portfolios beyond companion animals, the operational demands on commercial teams will intensify. Virtual assistants are increasingly the connective tissue that holds lean teams together through launch cycles and lifecycle management phases.
Sources
- American Veterinary Medical Association, Economic Summary of Veterinary Pharmaceuticals, 2024
- Regulatory Affairs Professionals Society, Veterinary Regulatory Coordinator Workload Survey, 2024
- Bureau of Labor Statistics, Occupational Employment and Wage Statistics, 2024
- Veterinary Pharmacovigilance Consortium, Adverse Event Triage Benchmarking Report, 2024
- Animal Health Industry Conference Panel Proceedings, 2025